Tag: Nestlé Health Science
Seres Therapeutics gets FDA priority review designation for SER-109 in rCDI
Seres Therapeutics has secured priority review designation from the US Food and Drug Administration (FDA) for SER-109, its investigational oral microbiome therapeutic for the prevention ... Read More
Butterfly to sell majority stake in Orgain to Nestlé Health Science
Private equity firm Butterfly has signed a deal to divest a majority stake in Orgain, a plant-based functional nutrition platform, to Nestlé Health Science. The ... Read More
Nestlé to acquire core brands of vitamins manufacturer Bountiful for $5.7bn
Nestlé has signed a deal worth $5.75 billion with KKR to acquire core brands of Bountiful, a US manufacturer of vitamins and nutritional supplements. Included ... Read More
Seres Therapeutics begins phase 1b trial of SER-301 in ulcerative colitis
Seres Therapeutics has dosed the first patient in a phase 1b clinical trial, which is assessing SER-301 for the treatment of active mild-to-moderate ulcerative colitis ... Read More
Nestlé to fully own Aimmune Therapeutics through $2bn deal
Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in ... Read More
Nestlé to acquire majority stake in US collagen brand Vital Proteins
Nestlé Health Science (NHSc) has agreed to acquire a majority stake in Vital Proteins, a US collagen brand and a lifestyle and wellness platform that ... Read More
Nestlé increases stake in Aimmune Therapeutics after Palforzia FDA approval
Aimmune Therapeutics, which has recently bagged approval from the US Food and Drug Administration (FDA) for its peanut allergy drug PALFORZIA (formerly AR101), has secured ... Read More